.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,559,269

« Back to Dashboard

Claims for Patent: 5,559,269

Title: 3,3-diphenylpropylamines, their use and preparation
Abstract:The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R.sup.1 signifies hydrogen or methyl, R.sup.2 and R.sup.3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R.sup.4 and R.sup.5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R.sup.4 and R.sup.5 may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The invention also relates to methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs ##STR1##
Inventor(s): Johansson; Rolf A. (Huddinge, SE), Moses; Pinchas (Satsj o-Boo, SE), Nilvebrant; Lisbeth (Bromma, SE), Sparf; Bengt .ANG.. (Tr.ang.ngsund, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:08/432,113
Patent Claims: 1. A 3,3-diphenylpropylamine of formula I ##STR12## wherein R.sup.1 represents hydrogen or methyl, R.sup.2 and R.sup.3 independently represent hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II ##STR13## wherein R.sup.4 and R.sup.5 represent non-aromatic hydrocarbyl groups, which are the same or different and which together contain at least three carbon atoms, and wherein R.sup.4 and R.sup.5 may form a ring together with the amine nitrogen; or a physiologically acceptable acid salt thereof.

2. The 3,3-diphenylpropylamine according to claim 1, wherein each of R.sup.4 and R.sup.5 independently represents a saturated hydrocarbyl group.

3. The 3,3-diphenylpropylamines according to claim 1 wherein at least one of R.sup.4 and R.sup.5 comprises a branched carbon chain.

4. The 3,3-diphenylpropylamine according to claim 1, wherein X is a moiety selected from the group consisting of formulas a) to h): ##STR14##

5. The 3,3-diphenylpropylamine according to claim 1, wherein the HOCH.sub.2 -group is in the 5-position on the phenyl ring, R.sup.2 is hydrogen and R.sup.3 is hydrogen or hydroxy.

6. The 3,3-diphenylpropylamines according to claim 1, selected from N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine, its salts with physiologically acceptable acids, racemates thereof and individual enantiomers thereof.

7. A pharmaceutical composition comprising an effective amount of a 3,3-diphenylpropylamine according to claim 1 and a compatible pharmaceutical carrier.

8. A method for preparing a 3,3-diphenylpropylamine according to claim 1, comprising:

a) reducing the group R.sup.6 CO of a 3,3-diphenylpropylamine of formula III ##STR15## wherein R.sup.1 to R.sup.3 and X are as defined above, R.sup.6 is hydrogen or R.sup.7 O, where R.sup.7 is hydrogen, alkyl, alkenyl, alkynyl or aryl, and any hydroxy groups may be protected, such as by methylation or benzylation, or

b) reacting a reactively esterified 3,3-diphenylpropanol of formula IV ##STR16## wherein R.sup.1 to R.sup.3 are as defined above, any hydroxy groups may be protected, and wherein Y is a leaving group, with an amine of formula V

wherein X is as defined above, or

c) reducing a 3,3-diphenylpropionamide of formula VI ##STR17## wherein R.sup.1 to R.sup.3 and X are as defined above and any hydroxy groups may be protected, or

d) N-methylating a secondary 3,3-diphenylpropylamine of formula VII ##STR18## wherein R.sup.1 to R.sup.3 and X are as defined above and any hydroxy groups may be protected, and wherein Z has the same meaning as R.sup.4 and R.sup.5 with the exception of methyl, or

e) reducing a 3,3-diphenylpropenamine of formula VIIIa or a 3,3-diphenylpropylamine of formula VIIIb ##STR19## wherein R.sup.1 to R.sup.3 and X are as defined above and any hydroxy groups may be protected, and W signifies a hydroxy group or a halogen atom, or

f) reacting a diphenylpropylamine of formula IX ##STR20## wherein R.sup.1 to R.sup.3 and X are as defined above, and Hal is halogen, with formaldehyde or a formaldehyde equivalent, or

g) oxidizing the methyl group of a diphenylpropylamine of formula X ##STR21## wherein R.sup.1 to R.sup.3 and X are as defined above, and i) when necessary splitting off hydroxy protecting groups in the compounds obtained, if desired after mono- or di-halogenation of one or both of the phenyl rings, and/or

ii) if desired converting the obtained bases of formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or

iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers, and/or

iv) if desired methylating an ortho-hydroxy group in an obtained compound of formula I, wherein R.sup.1 is hydrogen and/or R.sup.3 is hydroxy.

9. The 3,3-diphenylpropylamine according to claim 1, wherein said compound is in the form of a racemic mixture of optical isomers.

10. The 3,3-diphenylpropylamine according to claim 1, wherein said compound is an individual enantiomer.

11. The 3,3-diphenylpropylamine according to claim 2, wherein R.sup.4 and R.sup.5 independently represent a C.sub.1-8 -alkyl group or adamantyl and the total number of carbon atoms contained in R.sup.4 and R.sup.5 is at least four carbon atoms.

12. The 3,3-diphenylpropylamine according to claim 11, wherein R.sup.4 and R.sup.5 independently represent a C.sub.1-6 -alkyl group.

13. The 3,3-diphenylpropylamine according to claim 5, wherein R.sup.3 is in the 2-position on the phenyl ring.

14. A method for treating acetylcholine-mediated disorders which comprises administering to a patient in need thereof an effective amount of a 3,3-diphenylpropylamine as claimed in claim 1.

15. The method according to claim 14, wherein said disorder is urinary incontinence.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc